Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 6—June 2021

Macrolide-Resistant Mycoplasma pneumoniae Infections in Children, Ohio, USA

Mariana M. Lanata1, Huanyu Wang, Kathy Everhart, Melisa Moore-Clingenpeel, Octavio Ramilo, and Amy LeberComments to Author 
Author affiliation: Nationwide Children’s Hospital, Columbus, Ohio, USA

Main Article

Table 4

Risk factors for longer duration of hospitalization in children hospitalized with Mycoplasma pneumoniae infection, Ohio, USA, 2015–2019*

Risk factor Univariate analysis
Multivariable analysis
RR (95% CI) p value aRR (95% CI) p value
Female sex 0.85 (0.63–1.15) 0.2852
Age, y 0.98 (0.95–1.01) 0.2213
Underlying condition 1.25 (0.92–1.71) 0.1592
Any previous visit 0.83 (0.58–1.16) 0.2734
Macrolide resistance 2.91 (1.56–5.44) 0.0008 2.04 (0.97–4.32) 0.061
Abnormal respiratory examination 1.14 (0.77–1.7) 0.5103
Previous treatment with antimicrobial drugs 0.94 (0.69–1.27) 0.6882
Previous nonmacrolide antimicrobial drugs 0.97 (0.71–1.31) 0.8204
Positive viral test 0.96 (0.69–1.34) 0.8122
MRMp and positive viral test 1.67 (0.51–5.44) 0.3946

*Bold type indicates statistical significance. aRR, adjusted RR; MRMp, macrolide-resistant Mycoplasma pneumoniae; RR, relative risk.

Main Article

1Current affiliation: Marshall University, Huntington, West Virginia, USA.

Page created: March 30, 2021
Page updated: May 18, 2021
Page reviewed: May 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.